Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

IntroductionCabozantinib (XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR and CABOSUN trials, cabozantinib was approved for use in the first- and...

Full description

Bibliographic Details
Main Authors: Mehmet A. Bilen, James F. Jiang, Caroline S. Jansen, Jacqueline T. Brown, Lara R. Harik, Aarti Sekhar, Haydn Kissick, Shishir K. Maithel, Omer Kucuk, Bradley Carthon, Viraj A. Master
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
cabozantinib
renal cell carcinoma
neoadjuvant therapy
radical nephrectomy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.622134/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.622134/full

Similar Items